Logo.png
Vyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16
November 10, 2022 08:00 ET | Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Logo.png
Vyant Bio Announces One-for-Five Reverse Stock Split
November 01, 2022 08:00 ET | Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Logo.png
Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights
August 22, 2022 16:10 ET | Vyant Bio, Inc.
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into...
Logo.png
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
November 10, 2021 16:15 ET | Vyant Bio, Inc.
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...
Logo.png
Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021
November 09, 2021 09:15 ET | Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...